TAU researchers devise a novel probe to identify and measure microscopic cell activity
Chemiluminescence, or chemical light, is the principle behind the glow sticks (also known as light sticks) used at rock concerts and as quick tools to grab when the electricity goes out. But they can also be used to diagnose diseases by identifying concentrations of biological samples. A new mechanism developed by Tel Aviv University researchers produces a 3,000-times-brighter, water-resistant chemiluminescent probe with particular application to medical and cancer diagnosis.
The research found that tweaking the electronic structure of current probes improves their inherent fluorescence. This could lead to the invention of a new single-component system with multiple applications — including the detection and measurement of cellular activity that points to certain pathologies, such as cancer. The study was recently published in ACS Central Science.
Chemical structure of the “glow stick” probe.
“Chemiluminescence is considered one of the most sensitive methods used in diagnostic testing,” said Prof. Doron Shabat of TAU’s School of Chemistry, who led the research. “We have developed a method to prepare highly efficient compounds that emit light upon contact with a specific protein or chemical. These compounds can be used as molecular probes to detect cancerous cells, among other applications.”
Fixing a glitch
The research, conducted in collaboration with Dr. Christoph Bauer of Geneva University, repairs an energy-loss “glitch” in current chemiluminescent probes. Most systems use a mixture of one emitter molecule that detects the species of interest, and another two additional ingredients — a fluorophore and a soap-like substance called a surfactant — that amplify the signal to detectable levels. But energy is lost in the transfer process from the emitter molecule to the fluorophore, and surfactants are not biocompatible.
“As synthetic chemists, we knew how to link structure and function,” said Prof. Shabat. “By adding two key atoms, we created a much brighter probe than those currently on the market. In addition, this particular molecule is suitable for direct use in cells.”
Based on this molecule, the researchers developed sensors to detect several biologically relevant chemicals. They also used the chemiluminescent molecule to measure the activity of several enzymes and to image cells by microscopy.
“This gives us a new powerful methodology with which we can prepare highly efficient chemiluminescence sensors for the detection, imaging and analysis of various cell activities,” said Prof. Shabat. The researchers are currently exploring ways of amplifying the chemiluminescence of the new probes for in vivo imaging.
Learn more: A Glow Stick That Detects Cancer?
The Latest on: Cancer detection
- Mayo Clinic Q And A: Breast cancer screening and COVID-19on December 4, 2020 at 2:35 am
DEAR MAYO CLINIC: During a breast self-exam two months ago, I felt a lump. This month, the lump seems to have disappeared. My cousin, who had breast cancer, is suggesting I get it checked anyways. I'm ...
- Global Medical Radiation Detection, Monitoring and Safety Market Report 2020: Radiation Safety Technologies Take a Back Seat With -4.6% Revenue Blowon December 4, 2020 at 2:12 am
The "Medical Radiation Detection, Monitoring and Safety - Global Market Trajectory & Analytics" report has been added ...
- Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detectionon December 3, 2020 at 6:25 pm
Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding ...
- Akron City Councilman Rich Swirsky takes step back from job duties following cancer diagnosison December 3, 2020 at 12:16 pm
Ward 1 Councilman Rich Swirsky announced he has been diagnosed with acute myeloid leukemia and began chemotherapy this week.
- FDA approves drug for PET imaging of prostate canceron December 3, 2020 at 10:22 am
The U.S. Food and Drug Administration approved the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer, ...
via Google News and Bing News